Neurocrine Biosciences
NBIX
#1293
Rank
S$22.68 B
Marketcap
S$224.13
Share price
3.12%
Change (1 day)
16.97%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): S$8.95

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$8.96. In 2025 the company made an earnings per share (EPS) of S$6.19 an increase over its 2024 EPS that were of S$4.34.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$8.9544.53%
2025S$6.1942.6%
2024S$4.3433.07%
2023S$3.2657.76%
2022S$2.0769.47%
2021S$1.22-78.21%
2020S$5.60990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.090.62%
2016S-$2.0857.28%
2015S-$1.3225.61%
2014S-$1.0518.84%
2013S-$0.89-1085.71%
2012S$0.08996

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$0.91-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$7.52-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$39.70 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S-$0.26-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.61-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$6.66-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$9.70-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$1.97-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK